S
Shunichi Negoro
Researcher at Kindai University
Publications - 101
Citations - 9059
Shunichi Negoro is an academic researcher from Kindai University. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 31, co-authored 101 publications receiving 8492 citations.
Papers
More filters
Journal ArticleDOI
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Junji Tsurutani,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka +20 more
TL;DR: In this article, an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan was conducted.
Journal ArticleDOI
Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer
Kazumasa Noda,Yutaka Nishiwaki,Masaaki Kawahara,Shunichi Negoro,Takahiko Sugiura,A. Yokoyama,Masahiro Fukuoka,K. Mori,Koshiro Watanabe,Tomohide Tamura,Seiichiro Yamamoto,Nagahiro Saijo +11 more
TL;DR: Irinotecan plus cisplatin is an effective treatment for metastatic small-cell lung cancer and severe or life-threatening diarrhea was more frequent in the irinotican-plus-cisplatin group than in the etoposide-plus -cis Platin group.
Journal ArticleDOI
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.
Noriyuki Masuda,Masahiro Fukuoka,Yoko Kusunoki,Kaoru Matsui,Nobuhide Takifuji,Shinzoh Kudoh,Shunichi Negoro,Masayuki Nishioka,Kazuhiko Nakagawa,Minoru Takada +9 more
TL;DR: CPT-11 is an active agent against refractory or relapsed SCLC and deserves to be studied more closely as both a single agent and in combination with other drugs to treat patients with SclC.
Journal ArticleDOI
Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
Riichiroh Maruyama,Yutaka Nishiwaki,Tomohide Tamura,Nobuyuki Yamamoto,Masahiro Tsuboi,Kazuhiko Nakagawa,Tetsu Shinkai,Shunichi Negoro,Fumio Imamura,Kenji Eguchi,Koji Takeda,Akira Inoue,Keisuke Tomii,Masao Harada,Noriyuki Masuda,Haiyi Jiang,Yohji Itoh,Yukito Ichinose,Nagahiro Saijo,Masahiro Fukuoka +19 more
TL;DR: Gefitinib significantly improved objective response rate and quality of life versus docetaxel; progression-free survival, disease control rates, and symptom improvement were similar for the two treatments.
Journal ArticleDOI
Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)
Shinzoh Kudoh,Koji Takeda,Kazuhiko Nakagawa,Minoru Takada,Nobuyuki Katakami,Kaoru Matsui,Tetsu Shinkai,Toshiyuki Sawa,Isao Goto,Hiroshi Semba,Takashi Seto,Masahiko Ando,Taroh Satoh,Naruo Yoshimura,Shunichi Negoro,Masahiro Fukuoka +15 more
TL;DR: Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine, and may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.